| 1 | Exploring the potential of TGFβ as a diagnostic marker and therapeutic target against cancer | 3.8 | 27 | Citations (PDF) |
| 2 | Unveiling the potential of gene editing techniques in revolutionizing Cancer treatment: A comprehensive overview | 5.8 | 19 | Citations (PDF) |
| 3 | The Impact of Medicaid Expansion on Stage at Diagnosis of Melanoma Patients: A Retrospective Study | 2.7 | 2 | Citations (PDF) |
| 4 | DNA walk of specific fused oncogenes exhibit distinct fractal geometric characteristics in nucleotide patterns | 2.1 | 0 | Citations (PDF) |
| 5 | The expanding role of the receptor tyrosine kinase MET as a therapeutic target in non-small cell lung cancer | 5.3 | 17 | Citations (PDF) |
| 6 | Strategic advancements in targeting the PI3K/AKT/mTOR pathway for Breast cancer therapy | 3.8 | 63 | Citations (PDF) |
| 7 | Axl Regulation of NK Cell Activity Creates an Immunosuppressive Tumor Immune Microenvironment in Head and Neck Cancer | 2.7 | 3 | Citations (PDF) |
| 8 | Treatment Approaches for Oligoprogressive Non-Small Cell Lung Cancer: A Review of Ablative Radiotherapy | 2.7 | 5 | Citations (PDF) |
| 9 | Conformational dynamics and multimodal interaction of Paxillin with the focal adhesion targeting domain | 8.2 | 10 | Citations (PDF) |
| 10 | Metabolic reprogramming in breast cancer: Pathways driving progression, drug resistance, and emerging therapeutics | 5.8 | 19 | Citations (PDF) |
| 11 | Molecular PET imaging: Unlocking the secrets of cancer metabolism | 3.8 | 15 | Citations (PDF) |
| 12 | Targeting the oncoprotein RLIP as novel therapy for ovarian cancer | 2.8 | 2 | Citations (PDF) |
| 13 | Current paradigm of EGFR in non-small cell lung cancer: A long way forward | 6.2 | 4 | Citations (PDF) |
| 14 | Machine Learning Models for Predicting Gynecological Cancers: Advances, Challenges, and Future Directions | 2.7 | 18 | Citations (PDF) |
| 15 | Immune Escape Strategies in Head and Neck Cancer: Evade, Resist, Inhibit, Recruit | 2.7 | 23 | Citations (PDF) |
| 16 | Comprehending phenotypic plasticity in cancer and evolution | 2.5 | 5 | Citations (PDF) |
| 17 | Emerging biomarkers and molecular targets for precision medicine in cervical cancer | 5.8 | 41 | Citations (PDF) |
| 18 | MerTK Drives Proliferation and Metastatic Potential in Triple-Negative Breast Cancer | 3.2 | 8 | Citations (PDF) |
| 19 | Leveraging Cancer Phenotypic Plasticity for Novel Treatment Strategies | 1.8 | 5 | Citations (PDF) |
| 20 | Nanoengineering Solutions for Cancer Therapy: Bridging the Gap between Clinical Practice and Translational Research | 1.8 | 13 | Citations (PDF) |
| 21 | A novel HLA-DQB2::MET gene fusion variant in lung adenocarcinoma with prolonged response to tepotinib: a case report | 1.3 | 5 | Citations (PDF) |
| 22 | Teriflunomide/leflunomide synergize with chemotherapeutics by decreasing mitochondrial fragmentation via DRP1 in SCLC | 2.5 | 10 | Citations (PDF) |
| 23 | Spatial iTME analysis of KRAS mutant NSCLC and immunotherapy outcome | 5.0 | 4 | Citations (PDF) |
| 24 | Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells | 2.7 | 333 | Citations (PDF) |
| 25 | Enhancing carboplatin sensitivity in ovarian cancer cells by blocking the mercapturic acid pathway transporter | 2.2 | 2 | Citations (PDF) |
| 26 | RBM10 Mutation as a Potential Negative Prognostic/Predictive Biomarker to Therapy in Non-Small-Cell Lung Cancer | 2.1 | 7 | Citations (PDF) |
| 27 | Phenotypic Plasticity and Cancer: A System Biology Perspective | 1.8 | 4 | Citations (PDF) |
| 28 | Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions | 1.8 | 63 | Citations (PDF) |
| 29 | Gynecological cancer tumor Microenvironment: Unveiling cellular complexity and therapeutic potential | 3.8 | 26 | Citations (PDF) |
| 30 | Comprehensive investigation of long non-coding RNA HOTAIR polymorphisms and cancer risk: a current meta-analysis encompassing 96,458 participants | 2.7 | 6 | Citations (PDF) |
| 31 | From Bench to Bedside: A Team’s Approach to Multidisciplinary Strategies to Combat Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma | 1.8 | 7 | Citations (PDF) |
| 32 | Next-Generation Immunotherapy: Advancing Clinical Applications in Cancer Treatment | 1.8 | 109 | Citations (PDF) |
| 33 | Artificial Intelligence–Driven Computational Approaches in the Development of Anticancer Drugs | 2.7 | 48 | Citations (PDF) |
| 34 | Intrinsic disorder, extraterrestrial peptides, and prebiotic life on the earth | 1.8 | 7 | Citations (PDF) |
| 35 | Precision oncology provides opportunities for targeting KRAS-inhibitor resistance | 10.6 | 51 | Citations (PDF) |
| 36 | A Systems Biology Approach for Addressing Cisplatin Resistance in Non-Small Cell Lung Cancer | 1.8 | 17 | Citations (PDF) |
| 37 | Prognostic significance of natural products against multidrug tumor resistance | 6.7 | 24 | Citations (PDF) |
| 38 | Integration of artificial intelligence in lung cancer: Rise of the machine | 5.3 | 61 | Citations (PDF) |
| 39 | Overcoming Barriers to Tobacco Cessation and Lung Cancer Screening among Racial and Ethnic Minority Groups and Underserved Patients in Academic Centers and Community Network Sites: The City of Hope Experience | 1.8 | 9 | Citations (PDF) |
| 40 | A Closer Look at EGFR Inhibitor Resistance in Non-Small Cell Lung Cancer through the Lens of Precision Medicine | 1.8 | 12 | Citations (PDF) |
| 41 | Assessment of Barriers and Challenges to Screening, Diagnosis, and Biomarker Testing in Early-Stage Lung Cancer | 2.7 | 26 | Citations (PDF) |
| 42 | Dual Axl/MerTK inhibitor INCB081776 creates a proinflammatory tumor immune microenvironment and enhances anti‐PDL1 efficacy in head and neck cancer | 1.4 | 11 | Citations (PDF) |
| 43 | LSD1-targeted therapy—a multi-purpose key to unlock immunotherapy in small cell lung cancer | 1.3 | 9 | Citations (PDF) |
| 44 | Recent Advancement in Breast Cancer Research: Insights from Model Organisms—Mouse Models to Zebrafish | 2.7 | 26 | Citations (PDF) |
| 45 | The innate effects of plant secondary metabolites in preclusion of gynecologic cancers: Inflammatory response and therapeutic action | 5.8 | 16 | Citations (PDF) |
| 46 | Radiation Sensitivity: The Rise of Predictive Patient-Derived Cancer Models | 2.3 | 1 | Citations (PDF) |
| 47 | Intrinsically disordered proteins and conformational noise: The hypothesis a decade later | 2.5 | 10 | Citations (PDF) |
| 48 | Clinical Network Systems Biology: Traversing the Cancer Multiverse | 1.8 | 13 | Citations (PDF) |
| 49 | Differential Distribution of Brain Metastases from Non-Small Cell Lung Cancer Based on Mutation Status | 1.8 | 3 | Citations (PDF) |
| 50 | Selpercatinib and Pralsetinib Induced Chylous Ascites in RET-Rearranged Lung Adenocarcinoma: A Case Series | 2.1 | 14 | Citations (PDF) |
| 51 | An LC–MS/MS Method for Simultaneous Determination of LB-100 and Its Active Metabolite, Endothall, in Human Plasma | 0.8 | 1 | Citations (PDF) |
| 52 | Targeted Therapies in Early-Stage Resectable Non–Small-Cell Lung Cancer: New Kids on the Block | 1.1 | 2 | Citations (PDF) |
| 53 | Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer | 8.2 | 76 | Citations (PDF) |
| 54 | A Nexus between Genetic and Non-Genetic Mechanisms Guides KRAS Inhibitor Resistance in Lung Cancer | 3.1 | 2 | Citations (PDF) |
| 55 | Artificial intelligence and allied subsets in early detection and preclusion of gynecological cancers | 5.8 | 39 | Citations (PDF) |
| 56 | Epigenetic landscape of small cell lung cancer: small image of a giant recalcitrant disease | 10.7 | 55 | Citations (PDF) |
| 57 | MicroRNA-1: Diverse role of a small player in multiple cancers | 3.9 | 21 | Citations (PDF) |
| 58 | Near-Complete Response to Combined Pembrolizumab and Platinum-Doublet in a Patient With STK11/KRAS Mutated Advanced Lung Adenocarcinoma | 2.1 | 4 | Citations (PDF) |
| 59 | Co-opting disorder into order: Intrinsically disordered proteins and the early evolution of complex multicellularity | 5.7 | 12 | Citations (PDF) |
| 60 | Novel Therapeutic Targets and Immune Dysfunction in Malignant Pleural Mesothelioma | 2.6 | 9 | Citations (PDF) |
| 61 | Abstract PO-009: Assessment of geographic and racial/ethnic variables in tobacco use among cancer patients in a widely dispersed academic-led cancer care network 2022, , | | 0 | Citations (PDF) |
| 62 | Abstract PO-011: Use of clinician and nurse tobacco cessation champions to implement a tobacco control program in a geographically disseminated academic center-led clinical network analyzed by patient racial/ethnic group 2022, , | | 1 | Citations (PDF) |
| 63 | Postoperative Radiation Therapy Should Be Used for Completely Resected Stage III-N2 NSCLC in Select Patients | 1.6 | 15 | Citations (PDF) |
| 64 | Intrinsically Disordered Proteins: Critical Components of the Wetware | 43.1 | 90 | Citations (PDF) |
| 65 | Small Cell Lung Cancer Transformation following Treatment in EGFR-Mutated Non-Small Cell Lung Cancer | 1.8 | 30 | Citations (PDF) |
| 66 | Intrinsically disordered proteins: Ensembles at the limits of Anfinsen's dogma | 2.4 | 42 | Citations (PDF) |
| 67 | Dynamic Phenotypic Switching and Group Behavior Help Non-Small Cell Lung Cancer Cells Evade Chemotherapy | 3.1 | 25 | Citations (PDF) |
| 68 | Infectious complications of immune checkpoint inhibitors in solid organ malignancies | 2.0 | 33 | Citations (PDF) |
| 69 | AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer | 2.1 | 17 | Citations (PDF) |
| 70 | Machine learning to refine prognostic and predictive nodal burden thresholds for post-operative radiotherapy in completely resected stage III-N2 non-small cell lung cancer | 1.5 | 19 | Citations (PDF) |
| 71 | Leveraging deep learning algorithms for synthetic data generation to design and analyze biological networks | 1.0 | 32 | Citations (PDF) |
| 72 | Chemokines and NSCLC: Emerging role in prognosis, heterogeneity, and therapeutics | 10.7 | 61 | Citations (PDF) |
| 73 | An Updated Review on Radiation Treatment Management in Thymus Cancers | 2.1 | 6 | Citations (PDF) |
| 74 | Ablative Radiotherapy as a Strategy to Overcome TKI Resistance in EGFR-Mutated NSCLC | 2.7 | 8 | Citations (PDF) |
| 75 | Intrinsically disordered BMP4 morphogen and the beak of the finch: Co-option of an ancient axial patterning system | 5.7 | 9 | Citations (PDF) |
| 76 | RLIP: A necessary transporter protein for translating oxidative stress into pro-obesity and pro-carcinogenic signaling | 5.8 | 6 | Citations (PDF) |
| 77 | Addressing Drug Resistance in Cancer: A Team Medicine Approach | 1.8 | 11 | Citations (PDF) |
| 78 | Utilization of model-agnostic explainable artificial intelligence frameworks in oncology: a narrative review | 1.0 | 81 | Citations (PDF) |
| 79 | Clinical and Molecular Features of KRAS-Mutated Lung Cancer Patients Treated with Immune Checkpoint Inhibitors | 2.7 | 25 | Citations (PDF) |
| 80 | Pyramidal Decision Support Framework Leverages Subspecialty Expertise across Enterprise to Achieve Superior Cancer Outcomes and Personalized, Precision Care Plans | 1.8 | 10 | Citations (PDF) |
| 81 | Targeting RLIP with CRISPR/Cas9 controls tumor growth | 2.2 | 21 | Citations (PDF) |
| 82 | Evaluation of Omics-Based Strategies for the Management of Advanced Lung Cancer | 2.7 | 10 | Citations (PDF) |
| 83 | Progressive Neurologic Changes in a Patient With Metastatic Non–Small-Cell Lung Cancer: Cancer Effects or a Secondary Diagnosis? | 2.7 | 0 | Citations (PDF) |
| 84 | Multicohort Retrospective Validation of a Predictive Biomarker for Topoisomerase I Inhibitors | 1.1 | 3 | Citations (PDF) |
| 85 | JNJ-64041757 (JNJ-757), a Live, Attenuated, Double-Deleted Listeria monocytogenes–Based Immunotherapy in Patients With NSCLC: Results From Two Phase 1 Studies | 0.6 | 12 | Citations (PDF) |
| 86 | The Effects of Time to Treatment Initiation for Patients With Non–small-cell Lung Cancer in the United States | 2.1 | 57 | Citations (PDF) |
| 87 | The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC) | 5.3 | 141 | Citations (PDF) |
| 88 | Integrating Academic and Community Cancer Care and Research through Multidisciplinary Oncology Pathways for Value-Based Care: A Review and the City of Hope Experience | 1.8 | 29 | Citations (PDF) |
| 89 | Prevention of mammary carcinogenesis in MMTV‐neu mice by targeting RLIP | 2.1 | 4 | Citations (PDF) |
| 90 | Co-stimulatory and co-inhibitory Immune Markers in Solid Tumors With
MET
Alterations | 1.4 | 2 | Citations (PDF) |
| 91 | RLIP depletion induces apoptosis associated with inhibition of JAK2/STAT3 signaling in melanoma cells | 2.2 | 5 | Citations (PDF) |
| 92 | Predicting Survival Duration With MRI Radiomics of Brain Metastases From Non-small Cell Lung Cancer | 1.7 | 37 | Citations (PDF) |
| 93 | RNA-based therapies: A cog in the wheel of lung cancer defense | 19.9 | 92 | Citations (PDF) |
| 94 | Disparate outcomes in nonsmall cell lung cancer by immigration status | 2.0 | 4 | Citations (PDF) |
| 95 | Germline mutations and age at onset of lung adenocarcinoma | 2.7 | 24 | Citations (PDF) |
| 96 | Group Behavior and Emergence of Cancer Drug Resistance | 10.6 | 43 | Citations (PDF) |
| 97 | Activating p53 function by targeting RLIP | 5.8 | 5 | Citations (PDF) |
| 98 | Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer | 11.0 | 56 | Citations (PDF) |
| 99 | Molecular and Clinical Features of Hospital Admissions in Patients with Thoracic Malignancies on Immune Checkpoint Inhibitors | 2.7 | 3 | Citations (PDF) |
| 100 | ST6GalNAc‐I promotes lung cancer metastasis by altering MUC5AC sialylation | 2.8 | 41 | Citations (PDF) |
| 101 | The Small Molecule BC-2059 Inhibits Wingless/Integrated (Wnt)-Dependent Gene Transcription in Cancer through Disruption of the Transducin β-Like 1-β-Catenin Protein Complex | 2.3 | 18 | Citations (PDF) |
| 102 | Twitter as a Tool to Spread Communication Regarding Genitourinary Cancers During the COVID-19 Pandemic | 0.5 | 1 | Citations (PDF) |
| 103 | Evaluation of Somatic Mutations in Solid Metastatic Pan-Cancer Patients | 2.7 | 10 | Citations (PDF) |
| 104 | Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy | 1.6 | 120 | Citations (PDF) |
| 105 | The Association between Polluted Neighborhoods andTP53-Mutated Non–Small Cell Lung Cancer | 0.6 | 24 | Citations (PDF) |
| 106 | Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM) | 4.2 | 12 | Citations (PDF) |
| 107 | Immunotherapy in Non-Small Cell Lung Cancer Patients with Brain Metastases: Clinical Challenges and Future Directions | 2.7 | 15 | Citations (PDF) |
| 108 | Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer | 1.3 | 13 | Citations (PDF) |
| 109 | Elevated Eosinophil Count Following Pembrolizumab Treatment for Non-Small Cell Lung Cancer | 0.3 | 5 | Citations (PDF) |
| 110 | Immune Checkpoint Inhibitor–Induced Myocarditis with Myositis/Myasthenia Gravis Overlap Syndrome: A Systematic Review of Cases | 2.4 | 201 | Citations (PDF) |
| 111 | Targeting CA-125 Transcription by Development of a Conditionally Replicative Adenovirus for Ovarian Cancer Treatment | 2.7 | 9 | Citations (PDF) |
| 112 | Improving Care for Patients With Stage III or IV NSCLC: Learnings for Multidisciplinary Teams From the ACCC National Quality Survey | 2.7 | 11 | Citations (PDF) |
| 113 | Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung CancerChest, 2021, 160, 1095-1107 | 0.8 | 36 | Citations (PDF) |
| 114 | Therapeutic Potential of Olaparib in Combination With Pembrolizumab in a Young Patient With a Maternally Inherited BRCA2 Germline Variant: A Research Report | 2.1 | 7 | Citations (PDF) |
| 115 | Improved Survival Outcomes in Medically Fit Patients With Early-Stage Non–Small-Cell Lung Cancer Undergoing Stereotactic Body Radiotherapy | 2.1 | 3 | Citations (PDF) |
| 116 | Targeting the mercapturic acid pathway for the treatment of melanoma | 6.7 | 8 | Citations (PDF) |
| 117 | Inhibitors of the Transcription Factor STAT3 Decrease Growth and Induce Immune Response Genes in Models of Malignant Pleural Mesothelioma (MPM) | 2.7 | 17 | Citations (PDF) |
| 118 | Protein conformational dynamics and phenotypic switching | 2.4 | 17 | Citations (PDF) |
| 119 | The Mitochondrion as an Emerging Therapeutic Target in Cancer | 8.4 | 184 | Citations (PDF) |
| 120 | SOX9: The master regulator of cell fate in breast cancer | 3.8 | 68 | Citations (PDF) |
| 121 | Presence and structure‐activity relationship of intrinsically disordered regions across mucins | 2.3 | 12 | Citations (PDF) |
| 122 | RLIP controls receptor-ligand signaling by regulating clathrin-dependent endocytosis | 5.8 | 8 | Citations (PDF) |
| 123 | Activation of EPHA2-ROBO1 Heterodimer by SLIT2 Attenuates Non-canonical Signaling and Proliferation in Squamous Cell Carcinomas | 2.5 | 11 | Citations (PDF) |
| 124 | Hyperprogression on immunotherapy with complete response to chemotherapy in a NSCLC patient with high PD-L1 and STK11 | 1.0 | 18 | Citations (PDF) |
| 125 | A Non-genetic Mechanism Involving the Integrin β4/Paxillin Axis Contributes to Chemoresistance in Lung Cancer | 2.5 | 36 | Citations (PDF) |
| 126 | Small Cell Lung Cancer from Traditional to Innovative Therapeutics: Building a Comprehensive Network to Optimize Clinical and Translational Research | 1.8 | 10 | Citations (PDF) |
| 127 | Lysocardiolipin acyltransferase regulates NSCLC cell proliferation and migration by modulating mitochondrial dynamics | 1.3 | 18 | Citations (PDF) |
| 128 | Salmonella-Based Therapy Targeting Indoleamine 2,3-Dioxygenase Restructures the Immune Contexture to Improve Checkpoint Blockade Efficacy | 2.5 | 22 | Citations (PDF) |
| 129 | Acquired Resistance to PD-1/PD-L1 Blockade in Lung Cancer: Mechanisms and Patterns of Failure | 2.7 | 44 | Citations (PDF) |
| 130 | Rapid progression of disease from immunotherapy following targeted therapy: insights into treatment management and sequence | 0.9 | 0 | Citations (PDF) |
| 131 | Role of immunotherapy and co-mutations on KRAS-mutant non- small cell lung cancer survival | 0.9 | 44 | Citations (PDF) |
| 132 | Therapeutic targeting of miRNA-216b in cancer | 6.7 | 18 | Citations (PDF) |
| 133 | Differentiating Peripherally-Located Small Cell Lung Cancer From Non-small Cell Lung Cancer Using a CT Radiomic Approach | 1.7 | 51 | Citations (PDF) |
| 134 | Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies | 1.8 | 23 | Citations (PDF) |
| 135 | Association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitors | 1.9 | 11 | Citations (PDF) |
| 136 | Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion | 28.7 | 712 | Citations (PDF) |
| 137 | Radiomic prediction of mutation status based on MR imaging of lung cancer brain metastases | 1.2 | 55 | Citations (PDF) |
| 138 | Implementing Lung Cancer Screening and Prevention in Academic Centers, Affiliated Network Offices and Collaborating Care Sites | 1.8 | 11 | Citations (PDF) |
| 139 | Complex Oncological Decision-Making Utilizing Fast-and-Frugal Trees in a Community Setting—Role of Academic and Hybrid Modeling | 1.8 | 6 | Citations (PDF) |
| 140 | Association of TGF-β1 Polymorphisms with Breast Cancer Risk: A Meta-Analysis of Case–Control Studies | 2.7 | 9 | Citations (PDF) |
| 141 | Dose-Escalation Trial of the ALK, MET & ROS1 Inhibitor, Crizotinib, in Patients with Advanced Cancer | 1.7 | 14 | Citations (PDF) |
| 142 | Precision medicine and actionable alterations in lung cancer: A single institution experience | 1.5 | 9 | Citations (PDF) |
| 143 | The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping | 6.0 | 71 | Citations (PDF) |
| 144 | Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti–c-Met Antibody, in Patients with Advanced Solid Tumors | 1.3 | 27 | Citations (PDF) |
| 145 | USP22 Interacts with PALB2 and Promotes Chemotherapy Resistance via Homologous Recombination of DNA Double-Strand Breaks | 2.6 | 25 | Citations (PDF) |
| 146 | Prolonged survival and response to tepotinib in a non-small-cell lung cancer patient with brain metastases harboring MET exon 14 mutation: a research report | 0.8 | 10 | Citations (PDF) |
| 147 | AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer | 4.5 | 40 | Citations (PDF) |
| 148 | Effects of selected deubiquitinating enzyme inhibitors on the proliferation and motility of lung cancer and mesothelioma cell lines | 3.7 | 1 | Citations (PDF) |
| 149 | Small Cell Lung Cancer Therapeutic Responses Through Fractal Measurements: From Radiology to Mitochondrial Biology | 1.8 | 11 | Citations (PDF) |
| 150 | Notch signaling in breast cancer: From pathway analysis to therapy | 6.7 | 118 | Citations (PDF) |
| 151 | Prolonged Pharmacokinetic Interaction Between Capecitabine and a CYP2C9 Substrate, Celecoxib | 1.3 | 12 | Citations (PDF) |
| 152 | The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategies | 5.2 | 107 | Citations (PDF) |
| 153 | Monitoring and Determining Mitochondrial Network Parameters in Live Lung Cancer Cells | 1.8 | 6 | Citations (PDF) |
| 154 | Phenotypic Switching of Naïve T Cells to Immune-Suppressive Treg-Like Cells by Mutant KRAS | 1.8 | 35 | Citations (PDF) |
| 155 | EPHA2 mutations with oncogenic characteristics in squamous cell lung cancer and malignant pleural mesothelioma | 3.3 | 27 | Citations (PDF) |
| 156 | RLIP inhibition suppresses breast-to-lung metastasis | 6.7 | 16 | Citations (PDF) |
| 157 | Optimal adjuvant therapy in clinically N2 non-small cell lung cancer patients undergoing neoadjuvant chemotherapy and surgery: The importance of pathological response and lymph node ratio | 1.9 | 25 | Citations (PDF) |
| 158 | Synergistic efficacy of RLIP inhibition and 2′‐hydroxyflavanone against DMBA‐induced mammary carcinogenesis in SENCAR mice | 2.1 | 13 | Citations (PDF) |
| 159 | Structural and Dynamical Order of a Disordered Protein: Molecular Insights into Conformational Switching of PAGE4 at the Systems Level | 3.1 | 24 | Citations (PDF) |
| 160 | Combined Checkpoint Inhibition and Chemotherapy: New Era of 1st-Line Treatment for Non-Small-Cell Lung Cancer | 3.2 | 35 | Citations (PDF) |
| 161 | Early mortality of stage IV non-small cell lung cancer in the United States | 1.4 | 11 | Citations (PDF) |
| 162 | RLIP: An existential requirement for breast carcinogenesis | 5.8 | 10 | Citations (PDF) |
| 163 | Anaplastic Lymphoma Kinase (ALK)-positive Tumors | 1.1 | 10 | Citations (PDF) |
| 164 | Ubiquitin-specific protease 22 is critical to in vivo angiogenesis, growth and metastasis of non-small cell lung cancer | 6.2 | 54 | Citations (PDF) |
| 165 | Opportunities for improving cancer treatment using systems biology | 1.3 | 6 | Citations (PDF) |
| 166 | The DNA walk and its demonstration of deterministic chaos—relevance to genomic alterations in lung cancer | 3.2 | 13 | Citations (PDF) |
| 167 | 2′-Hydroxyflavanone induced changes in the proteomic profile of breast cancer cells | 1.9 | 12 | Citations (PDF) |
| 168 | The Brigatinib Experience: A New Generation of Therapy for ALK-Positive Non-Small-Cell Lung Cancer | 1.7 | 6 | Citations (PDF) |
| 169 | EphB4: A promising target for upper aerodigestive malignancies | 5.8 | 21 | Citations (PDF) |
| 170 | Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma | 3.2 | 102 | Citations (PDF) |
| 171 | Untying the gordion knot of targeting MET in cancer | 6.0 | 22 | Citations (PDF) |
| 172 | B-Cell-Specific Diversion of Glucose Carbon Utilization Reveals a Unique Vulnerability in B Cell MalignanciesCell, 2018, 173, 470-484.e18 | 23.8 | 127 | Citations (PDF) |
| 173 | Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance) | 1.4 | 47 | Citations (PDF) |
| 174 | Capecitabine and Celecoxib as a Promising Therapy for Thymic Neoplasms | 1.1 | 5 | Citations (PDF) |
| 175 | Complete Pathologic Response When Adding Pembrolizumab to Neoadjuvant Chemotherapy in Stage IIIA Non–Small-Cell Lung Cancer | 2.4 | 6 | Citations (PDF) |
| 176 | Managing Patients With Relapsed Small-Cell Lung Cancer | 2.4 | 55 | Citations (PDF) |
| 177 | Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single‐agent checkpoint blockade | 5.2 | 39 | Citations (PDF) |
| 178 | 1556. Infectious Disease Complications with Use of Checkpoint Inhibitors in Solid Organ Malignancies | 0.7 | 2 | Citations (PDF) |
| 179 | Prostate-Associated Gene 4 (PAGE4): Leveraging the Conformational Dynamics of a Dancing Protein Cloud as a Therapeutic Target | 1.8 | 13 | Citations (PDF) |
| 180 | Inhibiting crosstalk between MET signaling and mitochondrial dynamics and morphology: a novel therapeutic approach for lung cancer and mesothelioma | 3.2 | 18 | Citations (PDF) |
| 181 | Metastasis of breast tumor cells to brain is suppressed by targeting RLIP alone and in combination with 2′-Hydroxyflavanone | 6.7 | 13 | Citations (PDF) |
| 182 | Stereotactic body radiation therapy (SBRT) for early-stage lung cancer in the elderly | 2.9 | 71 | Citations (PDF) |
| 183 | A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors | 1.3 | 15 | Citations (PDF) |
| 184 | Effective osimertinib treatment in a patient with discordant T790 M mutation detection between liquid biopsy and tissue biopsy | 2.1 | 6 | Citations (PDF) |
| 185 | Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations 2018, 6, | | 1,178 | Citations (PDF) |
| 186 | 2′‐Hydroxyflavanone inhibits in vitro and in vivo growth of breast cancer cells by targeting RLIP76 | 2.1 | 25 | Citations (PDF) |
| 187 | Differential Response of MET inhibition by Glesatinib (MGCD265) and Sitravatinib (MGCD516) in Non‐small Cell Lung Cancer and Malignant Mesothelioma | 2.3 | 0 | Citations (PDF) |
| 188 | A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive‐disease small cell lung cancer | 1.9 | 68 | Citations (PDF) |
| 189 | Loss of H2B monoubiquitination is associated with poor‐differentiation and enhanced malignancy of lung adenocarcinoma | 2.8 | 38 | Citations (PDF) |
| 190 | Canonical and alternative transcript expression of PAX6 and CXCR4 in pancreatic cancer | 1.1 | 5 | Citations (PDF) |
| 191 | The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy | 6.0 | 16 | Citations (PDF) |
| 192 | TOPK (T‐LAK cell‐originated protein kinase) inhibitor exhibits growth suppressive effect on small cell lung cancer | 2.9 | 33 | Citations (PDF) |
| 193 | MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale | 1.3 | 157 | Citations (PDF) |
| 194 | Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study | 1.6 | 39 | Citations (PDF) |
| 195 | Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL | 2.7 | 20 | Citations (PDF) |
| 196 | Empowering survivors after colorectal and lung cancer treatment: Pilot study of a Self-Management Survivorship Care Planning intervention | 2.1 | 43 | Citations (PDF) |
| 197 | Synergistic Anti-Cancer Effect of Baicalein and Metformin against Human Lung Cancer | 0.9 | 0 | Citations (PDF) |
| 198 | Value-Based Medicine and Integration of Tumor Biology | 4.5 | 7 | Citations (PDF) |
| 199 | Value-Based Medicine and Integration of Tumor Biology | 4.5 | 2 | Citations (PDF) |
| 200 | Tumor Heterogeneity and Therapeutic Resistance | 4.5 | 62 | Citations (PDF) |
| 201 | Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer | 2.1 | 1 | Citations (PDF) |
| 202 | Prognostic and Predictive Value inKRASin Non–Small-Cell Lung Cancer | 11.0 | 159 | Citations (PDF) |
| 203 | Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma | 2.3 | 25 | Citations (PDF) |
| 204 | Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment | 6.7 | 169 | Citations (PDF) |
| 205 | Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab | 1.3 | 39 | Citations (PDF) |
| 206 | Unique fractal evaluation and therapeutic implications of mitochondrial morphology in malignant mesothelioma | 2.7 | 38 | Citations (PDF) |
| 207 | Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial | 14.5 | 337 | Citations (PDF) |
| 208 | PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma | 2.7 | 25 | Citations (PDF) |
| 209 | Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization | 2.4 | 125 | Citations (PDF) |
| 210 | Systemic Therapies in the Treatment of Non-Small-Cell Lung Cancer Brain Metastases | 1.7 | 11 | Citations (PDF) |
| 211 | Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes? | 1.6 | 178 | Citations (PDF) |
| 212 | C. elegansand mutants with chronic nicotine exposure as a novel model of cancer phenotype | 3.2 | 5 | Citations (PDF) |
| 213 | Tumor Heterogeneity and Therapeutic Resistance | 4.5 | 14 | Citations (PDF) |
| 214 | Concurrent EGFR Mutation and ALK Translocation in Non-Small Cell Lung Cancer | 0.3 | 26 | Citations (PDF) |
| 215 | Role Played by Paxillin and Paxillin Tyrosine Phosphorylation in Hepatocyte Growth Factor/Sphingosine‐1‐Phosphate‐Mediated Reactive Oxygen Species Generation, Lamellipodia Formation, and Endothelial Barrier Function | 1.3 | 24 | Citations (PDF) |
| 216 | Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic Pathway Analysis in Lung Cancer | 2.7 | 23 | Citations (PDF) |
| 217 | Multiple Endocrine Disruption by the MET/ALK Inhibitor Crizotinib in Patients With Non–small Cell Lung Cancer | 1.1 | 10 | Citations (PDF) |
| 218 | HABP2 is a Novel Regulator of Hyaluronan-Mediated Human Lung Cancer Progression | 1.7 | 37 | Citations (PDF) |
| 219 | Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors | 6.8 | 756 | Citations (PDF) |
| 220 | A new PET/CT volumetric prognostic index for non-small cell lung cancer | 1.9 | 23 | Citations (PDF) |
| 221 | Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Who Previously Progressed on Erlotinib | 4.5 | 81 | Citations (PDF) |
| 222 | Lung cancer—a fractal viewpoint | 53.1 | 191 | Citations (PDF) |
| 223 | Engineering Synthetic Antibody Inhibitors Specific for LD2 or LD4 Motifs of Paxillin | 3.0 | 10 | Citations (PDF) |
| 224 | Leptomeningeal carcinomatosis in esophageal cancer: a case series and systematic review of the literature | 0.6 | 27 | Citations (PDF) |
| 225 | AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma | 4.5 | 113 | Citations (PDF) |
| 226 | A Multicenter Phase I Study of Pazopanib in Combination with Paclitaxel in First-Line Treatment of Patients with Advanced Solid Tumors | 1.3 | 31 | Citations (PDF) |
| 227 | Diagnostic Challenges in Non-Small-Cell Lung Cancer: An Integrated Medicine Approach | 1.7 | 22 | Citations (PDF) |
| 228 | PAX3 and FOXD3 Promote CXCR4 Expression in Melanoma | 1.3 | 24 | Citations (PDF) |
| 229 | ROS1 rearranged non-small cell lung cancer brain metastases respond to low dose radiotherapy | 1.0 | 7 | Citations (PDF) |
| 230 | Whole-animal mounts of Caenorhabditis elegans for 3D imaging using atomic force microscopy | 2.4 | 11 | Citations (PDF) |
| 231 | Integrative Analysis of Head and Neck Cancer Identifies Two Biologically Distinct HPV and Three Non-HPV Subtypes | 4.5 | 352 | Citations (PDF) |
| 232 | Activating the Expression of Human K-rasG12D Stimulates Oncogenic Transformation in Transgenic Goat Fetal Fibroblast Cells | 1.5 | 5 | Citations (PDF) |
| 233 | The Mu Opioid Receptor Promotes Opioid and Growth Factor-Induced Proliferation, Migration and Epithelial Mesenchymal Transition (EMT) in Human Lung Cancer | 1.5 | 197 | Citations (PDF) |
| 234 | Brain metastases in non-small-cell lung cancer: better outcomes through current therapies and utilization of molecularly targeted approaches | 1.3 | 15 | Citations (PDF) |
| 235 | Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination with Bevacizumab in Patients with Advanced Solid Malignancies | 4.5 | 66 | Citations (PDF) |
| 236 | Expression of the EPHB4 receptor tyrosine kinase in head and neck and renal malignancies – implications for solid tumors and potential for therapeutic inhibition | 1.2 | 13 | Citations (PDF) |
| 237 | Fibroblast growth factor signaling and inhibition in non‐small cell lung cancer and their role in squamous cell tumors | 2.0 | 27 | Citations (PDF) |
| 238 | Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer | 2.1 | 16 | Citations (PDF) |
| 239 | Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy | 19.9 | 57 | Citations (PDF) |
| 240 | Analysis of 1,115 Patients Tested for
MET
Amplification and Therapy Response in the MD Anderson Phase I Clinic | 4.5 | 78 | Citations (PDF) |
| 241 | Geographic Variation in Radiologist Capacity and Widespread Implementation of Lung Cancer CT Screening | 1.3 | 25 | Citations (PDF) |
| 242 | Combined MET Inhibition and Topoisomerase I Inhibition Block Cell Growth of Small Cell Lung Cancer | 1.3 | 19 | Citations (PDF) |
| 243 | Non-small cell lung cancer is susceptible to induction of DNA damage responses and inhibition of angiogenesis by telomere overhang oligonucleotides | 6.7 | 23 | Citations (PDF) |
| 244 | Role of c-Met/Phosphatidylinositol 3-Kinase (PI3k)/Akt Signaling in Hepatocyte Growth Factor (HGF)-mediated Lamellipodia Formation, Reactive Oxygen Species (ROS) Generation, and Motility of Lung Endothelial Cells | 1.3 | 87 | Citations (PDF) |
| 245 | Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer | 19.4 | 1,892 | Citations (PDF) |
| 246 | Transactivation of the Receptor-tyrosine Kinase Ephrin Receptor A2 Is Required for the Low Molecular Weight Hyaluronan-mediated Angiogenesis That Is implicated in Tumor Progression | 1.3 | 38 | Citations (PDF) |
| 247 | Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-Negative Breast Cancer | 1.3 | 59 | Citations (PDF) |
| 248 | AXL Mediates Resistance to Cetuximab Therapy | 4.2 | 187 | Citations (PDF) |
| 249 | Mitochondrial dynamics: biology and therapy in lung cancer | 2.4 | 49 | Citations (PDF) |
| 250 | Dramatic Antitumor Effects of the Dual MET/RON Small-Molecule Inhibitor LY2801653 in Non–Small Cell Lung Cancer | 4.2 | 60 | Citations (PDF) |
| 251 | MET and PI3K/mTOR as a Potential Combinatorial Therapeutic Target in Malignant Pleural Mesothelioma | 1.5 | 53 | Citations (PDF) |
| 252 | EphB4 as a therapeutic target in mesothelioma | 2.1 | 33 | Citations (PDF) |
| 253 | MET As a Possible Target for Non–Small-Cell Lung Cancer | 12.3 | 193 | Citations (PDF) |
| 254 | Initial Clinical Sensitivity and Acquired Resistance to MET Inhibition in MET-Mutated Papillary Renal Cell Carcinoma | 12.3 | 29 | Citations (PDF) |
| 255 | Lipopolysaccharide-induced phosphorylation of c-Met tyrosine residue 1003 regulates c-Met intracellular trafficking and lung epithelial barrier function | 2.2 | 17 | Citations (PDF) |
| 256 | Critical Role for the Receptor Tyrosine Kinase EPHB4 in Esophageal Cancers | 4.2 | 51 | Citations (PDF) |
| 257 | Teaching Video Neuro
Images
: Myokymia and nerve hyperexcitability as components of Morvan syndrome due to malignant thymoma | 0.7 | 5 | Citations (PDF) |
| 258 | Critical Role of S1PR1 and Integrin β4 in HGF/c-Met-mediated Increases in Vascular Integrity | 1.3 | 47 | Citations (PDF) |
| 259 | A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non–Small Cell Lung Cancer | 4.5 | 219 | Citations (PDF) |
| 260 | Paxillin mutations affect focal adhesions and lead to altered mitochondrial dynamics | 3.2 | 43 | Citations (PDF) |
| 261 | The EphB4 Receptor Tyrosine Kinase Promotes Lung Cancer Growth: A Potential Novel Therapeutic Target | 1.5 | 70 | Citations (PDF) |
| 262 | Etoposide and Temozolomide in Combination for the Treatment of Progressive Small-Cell Lung Cancer Central Nervous System Metastases: Two Cases | 1.2 | 2 | Citations (PDF) |
| 263 | Lack of Association of C-Met-N375S Sequence Variant with Lung Cancer Susceptibility and Prognosis | 1.9 | 24 | Citations (PDF) |
| 264 | Characterization of NOL7 Gene Point Mutations, Promoter Methylation, and Protein Expression in Cervical Cancer | 1.1 | 13 | Citations (PDF) |
| 265 | Targeting myeloid-derived suppressor cells augments antitumor activity against lung cancer | 3.2 | 26 | Citations (PDF) |
| 266 | Hypofractionated Image-Guided Radiation Therapy for Patients with Limited Volume Metastatic Non-small Cell Lung Cancer | 1.6 | 97 | Citations (PDF) |
| 267 | Phase II Study of the Multitargeted Tyrosine Kinase Inhibitor XL647 in Patients with Non–Small-Cell Lung Cancer | 1.6 | 44 | Citations (PDF) |
| 268 | Three-Dimensional Stereoscopic Volume Rendering of Malignant Pleural Mesothelioma | 0.1 | 2 | Citations (PDF) |
| 269 | Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study | 14.5 | 1,234 | Citations (PDF) |
| 270 | Quality of Life After Radical Pleurectomy Decortication for Malignant Pleural Mesothelioma | 2.2 | 43 | Citations (PDF) |
| 271 | Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin’s lymphoma, and neuroblastoma | 2.5 | 30 | Citations (PDF) |
| 272 | A Novel Classification of Lung Cancer into Molecular Subtypes | 1.5 | 104 | Citations (PDF) |
| 273 | Differential expression of RON in small and non–small cell lung cancers | 1.6 | 33 | Citations (PDF) |
| 274 | Inhibition of mitochondrial fission prevents cell cycle progression in lung cancer | 2.3 | 557 | Citations (PDF) |
| 275 | Targeted and Cytotoxic Therapy in Coordinated Sequence (TACTICS): Erlotinib, Bevacizumab, and Standard Chemotherapy for Non–Small-Cell Lung Cancer, A Phase II Trial | 2.1 | 10 | Citations (PDF) |
| 276 | Proteomic characterization of non-small cell lung cancer in a comprehensive translational thoracic oncology database | 3.6 | 10 | Citations (PDF) |
| 277 | Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis | 14.5 | 874 | Citations (PDF) |
| 278 | Role of MetMAb (OA-5D5) in c-MET active lung malignancies | 1.9 | 49 | Citations (PDF) |
| 279 | MET and Phosphorylated MET as Potential Biomarkers in Lung Cancer | 1.2 | 28 | Citations (PDF) |
| 280 | Phase 2 Trial of Linifanib (ABT-869) in Patients with Advanced Non-small Cell Lung Cancer | 1.6 | 68 | Citations (PDF) |
| 281 | Bortezomib for Patients with Advanced-Stage Bronchioloalveolar Carcinoma: A California Cancer Consortium Phase II Study (NCI 7003) | 1.6 | 10 | Citations (PDF) |
| 282 | Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research | 0.2 | 4 | Citations (PDF) |
| 283 | Personalized Treatment of Lung Cancer | 2.9 | 39 | Citations (PDF) |
| 284 | Mind-mapping for lung cancer: Towards a personalized therapeutics approach | 2.7 | 29 | Citations (PDF) |
| 285 | Prognostic significance of angiogenesis and angiogenic growth factors in nonsmall cell lung cancer | 2.7 | 51 | Citations (PDF) |
| 286 | An E3 ubiquitin ligase: c‐Cbl | 2.7 | 30 | Citations (PDF) |
| 287 | RON(MST1R)is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma | 3.2 | 82 | Citations (PDF) |
| 288 | Fyn Is Downstream of the HGF/MET Signaling Axis and Affects Cellular Shape and Tropism in PC3 Cells | 4.5 | 34 | Citations (PDF) |
| 289 | Novel Functional Germline Variants in the VEGF Receptor 2 Gene and Their Effect on Gene Expression and Microvessel Density in Lung Cancer | 4.5 | 77 | Citations (PDF) |
| 290 | Paxillin expression and amplification in early lung lesions of high-risk patients, lung adenocarcinoma and metastatic disease | 1.3 | 45 | Citations (PDF) |
| 291 | Takotsubo Cardiomyopathy in a Patient With Squamous Cell Esophageal Carcinoma | 12.3 | 8 | Citations (PDF) |
| 292 | Multicenter Phase II Trial of Motexafin Gadolinium and Pemetrexed for Second-Line Treatment in Patients with Non-small Cell Lung Cancer | 1.6 | 17 | Citations (PDF) |
| 293 | Durable Complete Response of Metastatic Gastric Cancer with Anti-Met Therapy Followed by Resistance at Recurrence | 6.8 | 111 | Citations (PDF) |
| 294 | The role of the c-Met pathway in lung cancer and the potential for targeted therapy | 2.1 | 115 | Citations (PDF) |
| 295 | Crizotinib: ALK/Met inhibitor, oncolytic | 0.2 | 15 | Citations (PDF) |
| 296 | Crizotinib: ALK/Met inhibitor, oncolytic | 0.2 | 3 | Citations (PDF) |
| 297 | Rapid and Dramatic Radiographic and Clinical Response to an ALK Inhibitor (Crizotinib, PF02341066) in an ALK Translocation-Positive Patient with Non-small Cell Lung Cancer | 1.6 | 73 | Citations (PDF) |
| 298 | CBL Is Frequently Altered in Lung Cancers: Its Relationship to Mutations in MET and EGFR Tyrosine Kinases | 1.5 | 101 | Citations (PDF) |
| 299 | EphA2 Mutation in Lung Squamous Cell Carcinoma Promotes Increased Cell Survival, Cell Invasion, Focal Adhesions, and Mammalian Target of Rapamycin Activation | 1.3 | 108 | Citations (PDF) |
| 300 | Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer | 19.4 | 4,327 | Citations (PDF) |
| 301 | Novel Oncogenic Mutations of CBL in Human Acute Myeloid Leukemia That Activate Growth and Survival Pathways Depend on Increased Metabolism | 1.3 | 52 | Citations (PDF) |
| 302 | MET molecular mechanisms and therapies in lung cancer | 2.3 | 64 | Citations (PDF) |
| 303 | The role of chemokine receptor CXCR4 in lung cancer | 3.2 | 64 | Citations (PDF) |
| 304 | NADPH oxidases regulate cell growth and migration in myeloid cells transformed by oncogenic tyrosine kinases | 3.6 | 101 | Citations (PDF) |
| 305 | Expression Patterns of PAX5, c-Met, and Paxillin in Neuroendocrine Tumors of the Lung | 1.7 | 44 | Citations (PDF) |
| 306 | The Role of EGFR Inhibition in the Treatment of Non-Small Cell Lung Cancer | 2.4 | 61 | Citations (PDF) |
| 307 | PAX6 Is Expressed in Pancreatic Cancer and Actively Participates in Cancer Progression through Activation of the MET Tyrosine Kinase Receptor Gene | 1.3 | 55 | Citations (PDF) |
| 308 | Ethnic Differences and Functional Analysis of MET Mutations in Lung Cancer | 4.5 | 186 | Citations (PDF) |
| 309 | Role of c-Met in Cancer: Emphasis on Lung Cancer | 2.9 | 55 | Citations (PDF) |
| 310 | PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription | 1.9 | 108 | Citations (PDF) |
| 311 | FYN
is overexpressed in human prostate cancer | 2.1 | 83 | Citations (PDF) |
| 312 | The MET axis as a therapeutic target | 0.7 | 33 | Citations (PDF) |
| 313 | MET as a target for treatment of chest tumors | 1.9 | 117 | Citations (PDF) |
| 314 | MET Pathway as a Therapeutic Target | 1.6 | 70 | Citations (PDF) |
| 315 | MET, HGF, EGFR, and PXN Gene Copy Number in Lung Cancer Using DNA Extracts from FFPE Archival Samples and Prognostic Significance | 1.2 | 37 | Citations (PDF) |
| 316 | NADPH Oxidases Are Important Regulators of Growth and Migration in Myeloid Neoplasms.Blood, 2009, 114, 2190-2190 | 3.6 | 0 | Citations (PDF) |
| 317 | Expression and mutational analysis of MET in human solid cancers | 1.6 | 301 | Citations (PDF) |
| 318 | Effect of a c-Met-specific, ATP-competitive small-molecule inhibitor SU11274 on human ovarian carcinoma cell growth, motility, and invasion | 2.2 | 38 | Citations (PDF) |
| 319 | Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II consortia | 2.3 | 155 | Citations (PDF) |
| 320 | Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer | 3.4 | 196 | Citations (PDF) |
| 321 | C. elegans as a model organism for in vivo screening in cancer: effects of human c-Met in lung cancer affect C. elegans vulva phenotypes | 3.2 | 31 | Citations (PDF) |
| 322 | Randomized Phase II Study of Carboplatin and Etoposide With or Without thebcl-2Antisense Oligonucleotide Oblimersen for Extensive-Stage Small-Cell Lung Cancer: CALGB 30103 | 12.3 | 166 | Citations (PDF) |
| 323 | Biomarkers in Lung Cancer: From Early Detection to Novel Therapeutics and Decision Making | 1.0 | 56 | Citations (PDF) |
| 324 | Phase I Trial of Erlotinib-Based Multimodality Therapy for Inoperable Stage III Non-small Cell Lung Cancer | 1.6 | 66 | Citations (PDF) |
| 325 | EGFR-Targeted Therapeutics: Focus on SCCHN and NSCLC | 1.7 | 25 | Citations (PDF) |
| 326 | Novel Transforming Mutations of CBL in Human Acute Myeloid LeukemiaBlood, 2008, 112, 2948-2948 | 3.6 | 2 | Citations (PDF) |
| 327 | Lymphatic Vessel Density Is Not Associated With Lymph Node Metastasis in Non–Small Cell Lung Carcinoma | 1.7 | 20 | Citations (PDF) |
| 328 | Activation of HGF/c-Met pathway contributes to the reactive oxygen species generation and motility of small cell lung cancer cells | 2.2 | 54 | Citations (PDF) |
| 329 | Lung carcinoma in African Americans | 6.2 | 47 | Citations (PDF) |
| 330 | CD44 Regulates Hepatocyte Growth Factor-mediated Vascular Integrity | 1.3 | 117 | Citations (PDF) |
| 331 | Chemotherapy and High Dose Radiotherapy Followed by Resection for Locally Advanced Nonsmall Cell Lung Cancers | 1.1 | 9 | Citations (PDF) |
| 332 | Biomarker discovery in lung cancer—promises and challenges of clinical proteomics | 5.0 | 60 | Citations (PDF) |
| 333 | Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion | 4.2 | 168 | Citations (PDF) |
| 334 | Key Signaling Pathways and Targets in Lung Cancer Therapy | 2.1 | 12 | Citations (PDF) |
| 335 | Lysophosphatidic acid modulates c-Met redistribution and hepatocyte growth factor/c-Met signaling in human bronchial epithelial cells through PKC δ and E-cadherin | 2.8 | 31 | Citations (PDF) |
| 336 | c-Met and hepatocyte growth factor: Potential as novel targets in cancer therapy | 2.8 | 126 | Citations (PDF) |
| 337 | Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma | 1.3 | 62 | Citations (PDF) |
| 338 | Diffuse alveolar damage after a single dose of topotecan in a patient with pulmonary fibrosis and small cell lung cancer | 1.9 | 16 | Citations (PDF) |
| 339 | Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer | 2.6 | 32 | Citations (PDF) |
| 340 | A review of topoisomerase inhibition in lung cancer | 3.2 | 36 | Citations (PDF) |
| 341 | Gefitinib response of erlotinib-refractory lung cancer involving meninges—role of EGFR mutation | 6.2 | 118 | Citations (PDF) |
| 342 | Therapeutic targeting of receptor tyrosine kinases in lung cancer | 2.9 | 22 | Citations (PDF) |
| 343 | Molecular Biology of Malignant Mesothelioma: A Review | 1.5 | 16 | Citations (PDF) |
| 344 | Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen speciesBlood, 2005, 105, 1717-1723 | 3.6 | 221 | Citations (PDF) |
| 345 | c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention | 6.7 | 507 | Citations (PDF) |
| 346 | Novel Therapies in Lung Cancer | 1.5 | 4 | Citations (PDF) |
| 347 | Receptor Tyrosine Kinases and Inhibitors in Lung Cancer | 1.7 | 45 | Citations (PDF) |
| 348 | Modulation of c-Kit/SCF Pathway Leads to Alterations in Topoisomerase-I Activity in Small Cell Lung Cancer | 1.2 | 18 | Citations (PDF) |
| 349 | Targeted molecules in small cell lung cancer | 2.9 | 46 | Citations (PDF) |
| 350 | Targeting c-Kit mutations: basic science to novel therapies | 0.7 | 85 | Citations (PDF) |
| 351 | The role of ephrins and Eph receptors in cancer | 7.3 | 324 | Citations (PDF) |
| 352 | Integrin dependent protein tyrosine phosphorylation is a key regulatory event in collagen IV mediated adhesion and proliferation of human lung tumor cell line, Calu-1 | 2.2 | 18 | Citations (PDF) |
| 353 | Title is missing! | 6.8 | 473 | Citations (PDF) |
| 354 | p53 and Bcl-2 in Small-Cell Lung Cancer | 2.1 | 0 | Citations (PDF) |
| 355 | Benefit of Active Treatment in Non–Small-Cell Lung Cancer in Elderly Patients and Patients with Poor Performance Status | 2.1 | 4 | Citations (PDF) |
| 356 | Molecular and cellular biology of small cell lung cancer | 2.9 | 67 | Citations (PDF) |
| 357 | Small cell lung cancer: from molecular biology to novel therapeutics | 1.3 | 14 | Citations (PDF) |
| 358 | P-324 c-Met/HGF signaling through P13K with effects on cytoskeletal functions in small cell lung cancer | 1.9 | 1 | Citations (PDF) |
| 359 | Use of Temozolomide with Other Cytotoxic Chemotherapy in the Treatment of Patients with Recurrent Brain Metastases from Lung Cancer | 2.4 | 51 | Citations (PDF) |
| 360 | Vaccination With Irradiated Autologous Tumor Cells Engineered to Secrete Granulocyte-Macrophage Colony-Stimulating Factor Augments Antitumor Immunity in Some Patients With Metastatic Non–Small-Cell Lung Carcinoma | 12.3 | 282 | Citations (PDF) |
| 361 | Small-Cell Cancers, and an Unusual Reaction to Chemotherapy | 12.3 | 12 | Citations (PDF) |
| 362 | Unusual Problems in Breast Cancer and a Rare Lung Cancer Case | 12.3 | 5 | Citations (PDF) |
| 363 | 2-Methoxyestradiol alters cell motility, migration, and adhesionBlood, 2003, 102, 289-296 | 3.6 | 43 | Citations (PDF) |
| 364 | Mechanisms of Metastasis as Related to Receptor Tyrosine Kinases in Small-Cell Lung Cancer | 1.2 | 21 | Citations (PDF) |
| 365 | Vascular Endothelial Growth Factor-induced Migration of Multiple Myeloma Cells Is Associated with β1 Integrin- and Phosphatidylinositol 3-Kinase-dependent PKCα Activation | 1.3 | 166 | Citations (PDF) |
| 366 | ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction | 5.3 | 46 | Citations (PDF) |
| 367 | CD2 molecules redistribute to the uropod during T cell scanning: Implications for cellular activation and immune surveillance | 5.3 | 49 | Citations (PDF) |
| 368 | A Fragment of Paxillin Binds the α4Integrin Cytoplasmic Domain (Tail) and Selectively Inhibits α4-Mediated Cell Migration | 1.3 | 52 | Citations (PDF) |
| 369 | Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition | 7.3 | 380 | Citations (PDF) |
| 370 | Gemcitabine-induced radiation recall | 1.4 | 132 | Citations (PDF) |
| 371 | Differential expression and signaling of CBL and CBL-B in BCR/ABL transformed cells | 5.2 | 26 | Citations (PDF) |
| 372 | Gemcitabine and vinorelbine in patients with advanced lung cancer: preclinical studies and report of a phase I trial | 1.3 | 28 | Citations (PDF) |
| 373 | SHIP1, an SH2 Domain Containing Polyinositol-5-phosphatase, Regulates Migration through Two Critical Tyrosine Residues and Forms a Novel Signaling Complex with DOK1 and CRKL | 1.3 | 51 | Citations (PDF) |
| 374 | Chemokine Receptors CXCR-1/2 Activate Mitogen-activated Protein Kinase via the Epidermal Growth Factor Receptor in Ovarian Cancer Cells | 1.3 | 191 | Citations (PDF) |
| 375 | Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571 | 5.2 | 229 | Citations (PDF) |
| 376 | Case 1: Small Bowel Obstruction Due to Metastatic Lung Cancer | 12.3 | 15 | Citations (PDF) |
| 377 | The Noncatalytic Domain of Protein-tyrosine Phosphatase-PEST Targets Paxillin for Dephosphorylation in Vivo | 1.3 | 63 | Citations (PDF) |
| 378 | The BCR/ABL Tyrosine Kinase Induces Production of Reactive Oxygen Species in Hematopoietic Cells | 1.3 | 288 | Citations (PDF) |
| 379 | Role of the Cytoskeletal Protein Paxillin in Oncogenesis | 0.6 | 46 | Citations (PDF) |
| 380 | Molecular Cloning and Characterization of Human Trabeculin-α, a Giant Protein Defining a New Family of Actin-binding Proteins | 1.3 | 40 | Citations (PDF) |
| 381 | The Role of Focal Adhesion Kinase Binding in the Regulation of Tyrosine Phosphorylation of Paxillin | 1.3 | 133 | Citations (PDF) |
| 382 | Expression of the focal adhesion protein paxillin in lung cancer and its relation to cell motility | 5.2 | 83 | Citations (PDF) |
| 383 | Involvement of the adapter protein CRKL in integrin-mediated adhesion | 5.2 | 29 | Citations (PDF) |
| 384 | Role of the adapter protein CRKL in signal transduction of normal hematopoietic and BCR/ABL-transformed cells | 3.6 | 104 | Citations (PDF) |
| 385 | Cancer-associated retinopathy in a patient with non-small-cell lung carcinoma | 1.9 | 33 | Citations (PDF) |
| 386 | A cdc15-like adaptor protein (CD2BP1) interacts with the CD2 cytoplasmic domain and regulates CD2-triggered adhesion | 5.2 | 95 | Citations (PDF) |
| 387 | Steel Factor Induces Tyrosine Phosphorylation of CRKL and Binding of CRKL to a Complex Containing c-Kit, Phosphatidylinositol 3-Kinase, and p120CBL | 1.3 | 96 | Citations (PDF) |
| 388 | Involvement of p130Cas and p105HEF1, a Novel Cas-like Docking Protein, in a Cytoskeleton-dependent Signaling Pathway Initiated by Ligation of Integrin or Antigen Receptor on Human B Cells | 1.3 | 112 | Citations (PDF) |
| 389 | The Bovine Papillomavirus E6 Protein Binds to the LD Motif Repeats of Paxillin and Blocks Its Interaction with Vinculin and the Focal Adhesion Kinase | 1.3 | 82 | Citations (PDF) |
| 390 | Differential Signaling after β1 Integrin Ligation Is Mediated Through Binding of CRKL to p120 and p110 | 1.3 | 90 | Citations (PDF) |
| 391 | Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL | 7.3 | 101 | Citations (PDF) |
| 392 | Association of the Cas-like Molecule HEF1 with CrkL Following Integrin and Antigen Receptor Signaling in Human B-Cells: Potential Relevance to Neoplastic Lymphohematopoietic Cells | 1.0 | 40 | Citations (PDF) |
| 393 | The BCR/ABL oncogene alters interaction of the adapter proteins CRKL and CRK with cellular proteins | 3.6 | 45 | Citations (PDF) |
| 394 | The phosphatidylinositol polyphosphate 5-phosphatase SHIP and the protein tyrosine phosphatase SHP-2 form a complex in hematopoietic cells which can be regulated by BCR/ABL and growth factors | 5.2 | 73 | Citations (PDF) |
| 395 | Thrombopoietin induces activation of the phosphatidylinositol-3′ kinase pathway and formation of a complex containing p85PI3K and the protooncoprotein p120CBL | 2.5 | 35 | Citations (PDF) |
| 396 | BCR/ABL induces multiple abnormalities of cytoskeletal function. | 6.8 | 157 | Citations (PDF) |
| 397 | Role of Focal Adhesion Proteins in Signal Transduction and Oncogenesis | 0.6 | 62 | Citations (PDF) |
| 398 | The Related Adhesion Focal Tyrosine Kinase Forms a Complex with Paxillin in Hematopoietic Cells | 1.3 | 131 | Citations (PDF) |
| 399 | p130CAS Forms a Signaling Complex with the Adapter Protein CRKL in Hematopoietic Cells Transformed by the BCR/ABL Oncogene | 1.3 | 111 | Citations (PDF) |
| 400 | CRKL Links p210BCR/ABL with Paxillin in Chronic Myelogenous Leukemia Cells | 1.3 | 115 | Citations (PDF) |
| 401 | Molecular Cloning Of Human Paxillin, a Focal Adhesion Protein Phosphorylated by P210BCR/ABL | 1.3 | 252 | Citations (PDF) |
| 402 | Changes in Tc-99m radionuclide bone scan images and peripheralizatioin of marrow hematopoetic activity associated with the administration of granulocyte colony stimulating factor as an adjunct to dose-intensified chemotherapy for breast cancer | 2.7 | 10 | Citations (PDF) |
| 403 | Shc phosphorylation in myeloid cells is regulated by granulocyte macrophage colony-stimulating factor, interleukin-3, and steel factor and is constitutively increased by p210BCR/ABL. | 1.3 | 142 | Citations (PDF) |
| 404 | Altered membrane fluidity in rat hepatocytes during endotoxic shock | 2.4 | 12 | Citations (PDF) |
| 405 | Degradation and regurgitation of extracellular proteins by cultured mouse peritoneal macrophages and baby hamster kidney fibroblasts. Kinetic evidence that the transfer of proteins to lysosomes is not irreversible. | 1.3 | 41 | Citations (PDF) |
| 406 | Exploring the Next Frontier in Non–Small-Cell Lung Cancer With High MET and Mutated Epidermal Growth Factor Receptor | 12.3 | 0 | Citations (PDF) |
| 407 | Title is missing! 0 | | 1 | Citations (PDF) |
| 408 | Small Cell Transformation of EGFR-Mutant NSCLC Treated with Tyrosine Kinase Inhibition | 2.0 | 4 | Citations (PDF) |
| 409 | Current Clinical Paradigm and Therapeutic Advancements in Thymic Malignancies: A Narrative Review | 2.7 | 3 | Citations (PDF) |
| 410 | Hyperthermia-induced apoptosis: The role of magnetic nanoparticles in targeted delivery for breast cancer treatment | 5.8 | 8 | Citations (PDF) |
| 411 | RLIP depletion suppresses ovarian cancer growth and metastasis | 2.8 | 0 | Citations (PDF) |
| 412 | Emerging trends and treatment strategies in ovarian cancer: A comprehensive review | 3.5 | 4 | Citations (PDF) |
| 413 | Epitranscriptomic signatures of malignancy: how RNA modifications shape breast and ovarian tumor progression | 3.8 | 0 | Citations (PDF) |
| 414 | mRNA-based cancer vaccines: A new frontier in personalized immunotherapy | 5.8 | 4 | Citations (PDF) |
| 415 | Abstract 7127: RalBP1 inhibition: A novel therapy for prostate cancer | 4.2 | 0 | Citations (PDF) |
| 416 | Abstract 1807: RLIP depletion suppresses ovarian cancer growth and metastasis. | 4.2 | 0 | Citations (PDF) |
| 417 | Abstract 5997: Network based mapping reveals mechanistic drivers and targetable hubs contributing to Sotorasib resistance in KRAS G12C lung cancer | 4.2 | 0 | Citations (PDF) |
| 418 | STK11 as an Emerging Biomarker in Non-Small Cell Lung Cancer | 2.0 | 0 | Citations (PDF) |
| 419 | Chemoresistance in gynecologic cancers: mechanistic insights and emerging platforms to overcome drug failure | 2.8 | 5 | Citations (PDF) |
| 420 | Inflammation-driven transcriptional reprogramming in prostate cancer: Convergence of NFκB, JAK/STAT3, and epigenetic remodeling in castration-resistant disease | 6.7 | 0 | Citations (PDF) |
| 421 | AI-Driven Design of High Affinity Biomolecule–Drug Conjugates for Gynecological Cancer Therapy: An Up-to-Date Narrative Review | 2.7 | 0 | Citations (PDF) |
| 422 | PP01.31: Genomic Predictors of Response to Platinum-Based Chemotherapy and Immunotherapy in Malignant Pleural Mesothelioma | 1.6 | 0 | Citations (PDF) |
